Arbitron (ARB), Nielsen (NLSN) to Provide FTC More Time in Proposed Merger
Tweet Send to a FriendGet Alerts ARB Hot Sheet
Price: $46.79 +0.09%
Overall Analyst Rating:
NEUTRAL (
Up)
Dividend Yield: 0.9%
Revenue Growth %: +5.1%
Overall Analyst Rating:
NEUTRAL (
Up)Dividend Yield: 0.9%
Revenue Growth %: +5.1%
Trade ARB Now!
Arbitron Inc. (NYSE: ARB) announced that, following informal discussions with the staff at the Federal Trade Commission ("FTC"), Arbitron and Nielsen Holdings (NYSE: NLSN) have agreed to voluntarily provide the FTC with additional time in which to review the proposed merger of TNC Sub I Corporation, a wholly owned subsidiary of Nielsen, with and into Arbitron.
Nielsen, as the acquiring party, will withdraw and refile its pre-merger notification and report form under the Hart-Scott-Rodino Antitrust Improvements Act ("HSR"), which will restart the 30-day time frame for initial review of the transaction. The waiting period for the new filing will expire at 11:59 p.m. on March 8, 2013, unless earlier terminated by the FTC, or the FTC makes a formal request for additional information prior to the expiration of the waiting period.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Nielsen, as the acquiring party, will withdraw and refile its pre-merger notification and report form under the Hart-Scott-Rodino Antitrust Improvements Act ("HSR"), which will restart the 30-day time frame for initial review of the transaction. The waiting period for the new filing will expire at 11:59 p.m. on March 8, 2013, unless earlier terminated by the FTC, or the FTC makes a formal request for additional information prior to the expiration of the waiting period.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Bausch & Lomb near deal to sell to Valeant Pharmaceuticals (VRX) - WSJ
- Valeant (VRX) Continues Deal Hunt; Close to Buying Bausch & Lomb for $9B
- rue21 (RUE) Will be Acquired by Apax Partners for $42/Share
Create E-mail Alert Related Categories
Corporate News, Mergers and Acquisitions
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
